Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) for the treatment of resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): Phase 3 KEYNOTE-689
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要